SCHEMBL9768178

SCHEMBL9768178

CC(C)NCC(=O)c1ccc(O)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.53
GAA P10253 4/20 0.53
DBH P09172 1/20 0.53
RECQL P46063 1/20 0.53
ALPL P05186 3/20 0.51
ALPG P10696 3/20 0.51
CA12 O43570 4/20 0.49
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
CA7 P43166 4/20 0.49
CA9 Q16790 4/20 0.49
CA14 Q9ULX7 4/20 0.49
XDH P47989 1/20 0.49
MAPT P10636 6/20 0.46
ADRB2 P07550 4/20 0.46
TDP1 Q9NUW8 4/20 0.46
ADRB1 P08588 3/20 0.46
TSHR P16473 3/20 0.46
MAPK1 P28482 3/20 0.46
HSD17B10 Q99714 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391092 1.00 KDM4E (0.53) KDM4EGAADBHRECQLALPL
Hydrochloric Acid SCHEMBL11290306 0.98 KDM4E (0.51) KDM4EGAADBHRECQLALPL
SCHEMBL9768009 0.85 KDM4E (0.49) KDM4EGAADBHRECQLALPL
SCHEMBL31419983 0.80 ADRB2 (0.51) KDM4EGAARECQLALPGCA12
Adrenalone SCHEMBL123124 0.80 ALPG (0.55) KDM4EGAADBHRECQLALPL
Adrenalone SCHEMBL29550997 0.80 ALPG (0.55) KDM4EGAADBHRECQLALPL
SCHEMBL9768252 0.80 KDM4E (0.50) KDM4EGAADBHRECQLALPL
SCHEMBL25640423 0.80 ERCC1 (0.58) KDM4EGAADBHRECQLALPL
SCHEMBL21579056 0.79 ADRB3 (0.62) ADRB3ADRA1A
SCHEMBL10071964 0.79 SIGMAR1 (0.53) ALPLALPGADRB2ADRB1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555042-B1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE EMCURE PHARMACEUTICALS LTD (IN) 2021-07-21 EP claimed
US-10759738-B2 Process for preparation of isoproterenol hydrochloride EMCURE PHARMACEUTICALS LIMITED (IN) 2020-09-01 US claimed
EP-3555042-A1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE Emcure Pharmaceuticals Limited (IN) 2019-10-23 EP claimed
WO-2018127806-A1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE EMCURE PHARMACEUTICALS LIMITED (IN) 2018-07-12 WO claimed
EP-3555042-B1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE EMCURE PHARMACEUTICALS LTD (IN) 2021-07-21 EP disclosed
EP-3555042-B1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE EMCURE PHARMACEUTICALS LTD (IN) 2021-07-21 EP disclosed
US-10759738-B2 Process for preparation of isoproterenol hydrochloride EMCURE PHARMACEUTICALS LIMITED (IN) 2020-09-01 US disclosed
US-10759738-B2 Process for preparation of isoproterenol hydrochloride EMCURE PHARMACEUTICALS LIMITED (IN) 2020-09-01 US disclosed
EP-3555042-A1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE Emcure Pharmaceuticals Limited (IN) 2019-10-23 EP disclosed
EP-3555042-A1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE Emcure Pharmaceuticals Limited (IN) 2019-10-23 EP disclosed
WO-2018127806-A1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE EMCURE PHARMACEUTICALS LIMITED (IN) 2018-07-12 WO disclosed
WO-2018127806-A1 PROCESS FOR PREPARATION OF ISOPROTERENOL HYDROCHLORIDE EMCURE PHARMACEUTICALS LIMITED (IN) 2018-07-12 WO disclosed
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-11-06 US disclosed
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS EMORY UNIVERSITY (US) 2012-01-26 US disclosed
WO-2010107866-A2 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS EMORY UNIVERSITY (US) 2010-09-23 WO disclosed
US-5047592-A Selective hydrogenolysis process ETHYL CORPORATION (US) 1991-09-10 US disclosed
US-4594356-A Topical administering an adrenalone derivative KEY PHARMACEUTICALS, INC. (US) 1986-06-10 US disclosed
US-4147799-A Process for reducing blood pressure and blocking β-adrenergic receptor KYOWA HAKKO KOGYO CO., LTD. (JP) 1979-04-03 US disclosed
US-4094983-A \"KETO\" SYMPATHOMIMETIC AMINES INTERX RESEARCH CORPORATION (US) 1978-06-13 US disclosed
US-3922348-A 3{40 ,4{40 -Dihydroxy-2-(isopropylamino)acetophenone intraocular pressure lowering process MEAD JOHNSON & CO 1975-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT KDM4E 2077/4885GAA 294/4885DBH 14/4885
US-10759738-B2 Process for preparation of isoproterenol hydrochloride ADRA1A, ADRB1, ADRA2C KDM4E 2624/4885GAA 2476/4885DBH 52/4885
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT KDM4E 2077/4885GAA 294/4885DBH 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.